New and emerging treatments in psychiatry

About the course

As our understanding of the causes of mental illness has developed, a growing number of pharmacological and non-pharmacological interventions have shown potential as novel treatments. While some of these remain experimental, others are emerging into routine clinical practice in the UK and around the world.

Drawing on recent exciting research findings, many of these interventions shine a new light on the causes and pathologies associated with psychiatric illnesses and are paving the way towards the future of psychiatry. From psychedelics to gut microbiome, this two-day course will introduce clinicians to the major new interventions with strong or promising clinical evidence. Learners will become familiar with the sorts of treatments currently available through either clinical or research pathways and be able to recommend these to their patients where appropriate. Each session will be taught by well-known academic and clinical experts from the IoPPN/Maudsley who work at the frontier of mental health research including Prof Allan Young (KCL Chair of Mood Disorders) and Prof David Veale (director of the Maudsley national service for OCD and related disorders).

This course will cover topics such as psilocybin, ketamine, MDMA, cannabis, transcranial magnetic stimulation, triple chronotherapy, and gut microbiome.